What is Oruka Therapeutics, Inc.'s price / book?

Oruka Therapeutics, Inc. (ORKA) reported price / book of 5× in Q1 2026.

How has Oruka Therapeutics, Inc.'s price / book changed year-over-year?

Oruka Therapeutics, Inc.'s price / book increased by 374.1% year-over-year, from 1.1× to 5×.

What does price / book mean?

Market capitalization at the quarter end divided by shareholders' equity. The premium (or discount) the market assigns to the company's book equity.

Oruka Therapeutics, Inc. ORKA Price / book

Price / book at other companies

Bristol-Myers SquibbBMY

6.2×-1.0×

Eli LillyLLY

26.3×-20.7×

Johnson & JohnsonJNJ

7.3×+2.1×

AmgenAMGN

20.6×-6.3×

AbbVieABBV

261×+221×

Kymera TherapeuticsKYMR

4.4×+2.2×

Other financials

Income statement

See full

Revenue-—

Operating income-$36.4M-45.2%

Net income-$31.8M-51.5%

EPS (diluted)-$0.46+93.4%

Balance sheet

See full

Cash & equivalents$49.5M-40.7%

Total debt$1.8M+90.8%

Total equity$486.7M+33.4%

Total assets$504.5M+33.8%

Cash flow

See full

Operating cash flow-$23.6M-13.0%

CapEx$73.0K+462%

Free cash flow-$23.7M-13.3%

Valuation

See full

Market cap$4.36B+533%

Enterprise value$4.32B+690%

Returns & leverage

See full

Return on equity-27.3%-11.1pp

Debt / equity0×0.0×

Current ratio23.8×-6.3×

Where this comes from

Calculated from Oruka Therapeutics, Inc.’s reported figures.

market cap/total stockholders equity=5×

Based on the most recent quarter.

The official record: Oruka Therapeutics, Inc.’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Oruka Therapeutics, Inc.'s price / book.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Oruka Therapeutics, Inc.'s price / book?: Oruka Therapeutics, Inc. (ORKA) reported price / book of 5× in Q1 2026.
How has Oruka Therapeutics, Inc.'s price / book changed year-over-year?: Oruka Therapeutics, Inc.'s price / book increased by 374.1% year-over-year, from 1.1× to 5×.
What does price / book mean?: Market capitalization at the quarter end divided by shareholders' equity. The premium (or discount) the market assigns to the company's book equity.